Search Results - "KEISHO CHIN"

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data by Chen, Li-Tzong, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Sameshima, Hiroki, Kang, Yoon-Koo, Boku, Narikazu

“…Background Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction…”
Get full text

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab by Boku, Narikazu, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Nishiyama, Taihei, Chen, Li-Tzong, Kang, Yoon-Koo

“…Background ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ≥ 2…”
Get full text

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study by OHTSU, Atsushi, AJANI, Jaffer A, MURO, Kei, YEUL HONG KIM, FERRY, David, TEBBUTT, Niall C, AL-BATRAN, Salah-Eddin, SMITH, Heind, COSTANTINI, Chiara, RIZVI, Syed, LEBWOHL, David, VAN CUTSEM, Eric, BAI, Yu-Xian, BANG, Yung-Jue, CHUNG, Hyun-Cheol, PAN, Hong-Ming, SAHMOUD, Tarek, LIN SHEN, YEH, Kun-Huei, KEISHO CHIN

“…The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This…”
Get full text

ASO Author Reflections: How Should We Approach Borderline Resectable Esophageal Squamous Cell Carcinoma? by Suzuki, Takeshi, Okamura, Akihiko, Watanabe, Masayuki, Chin, Keisho

Get full text

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer by Wakatsuki, Takeru, Yamamoto, Noriko, Sano, Takeshi, Chin, Keisho, Kawachi, Hiroshi, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Matsushima, Tomohiro, Suenaga, Mitsukuni, Shinozaki, Eiji, Hiki, Naoki, Ishikawa, Yuichi, Yamaguchi, Kensei

“…Background There is growing interest in the clinical significance of intratumoral HER2 heterogeneity. Its prognostic and predictive impacts on trastuzumab…”
Get full text

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma by Ooki, Akira, Osumi, Hiroki, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei

“…Esophageal cancer (EC) remains a public health concern with a high mortality and disease burden worldwide. Esophageal squamous cell carcinoma (ESCC) is a…”
Get full text

A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study) by Takeuchi, Hiroya, Ito, Yoshinori, Machida, Ryunosuke, Kato, Ken, Onozawa, Masakatsu, Minashi, Keiko, Yano, Tomonori, Nakamura, Kenichi, Tsushima, Takahiro, Hara, Hiroki, Okuno, Tatsuya, Hironaka, Shuichi, Nozaki, Isao, Ura, Takashi, Chin, Keisho, Kojima, Takashi, Seki, Shiko, Sakanaka, Katsuyuki, Fukuda, Haruhiko, Kitagawa, Yuko

“…Definitive chemoradiotherapy (CRT) is the standard treatment for patients with locally advanced esophageal cancer (EC) who refuse surgery as the initial…”
Get full text

Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival by Ota, Yumiko, Takahari, Daisuke, Suzuki, Takeshi, Osumi, Hiroki, Nakayama, Izuma, Oki, Akira, Wakatsuki, Takeru, Ichimura, Takashi, Ogura, Mariko, Shinozaki, Eiji, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…Purpose In the ATTRACTION-2 trial, nivolumab significantly improved the survival of advanced gastric cancer patients. The pretreatment neutrophil-to-lymphocyte…”
Get full text

Additional Treatment Following Noncurative Endoscopic Resection for Esophageal Squamous Cell Carcinoma: A Comparison of Outcomes between Esophagectomy and Chemoradiotherapy by Kanie, Yasukazu, Okamura, Akihiko, Asari, Takao, Maruyama, Suguru, Sakamoto, Kei, Fujiwara, Daisuke, Kanamori, Jun, Imamura, Yu, Ishiyama, Akiyoshi, Yoshio, Toshiyuki, Tsuchida, Tomohiro, Chin, Keisho, Watanabe, Masayuki

“…Background Endoscopic resection (ER) has been widely implemented for cT1N0 esophageal squamous cell carcinoma (ESCC). Additional therapy, including…”
Get full text

The Combined Use of 5 or More Drugs Is a Factor Related to Lower Adherence to S-1 in S-1 and Oxaliplatin Treatment for Advanced Gastric Cancer by Kawakami, Kazuyoshi, Aoyama, Takeshi, Yokokawa, Takashi, Kobayashi, Kazuo, Takahari, Daisuke, Chin, Keisho, Ide, Tsugumi, Machida, Yoshiaki, Yamaguchi, Kensei, Hama, Toshihiro

“…S-1 plus oxaliplatin (SOX) is an established treatment for advanced gastric cancer. S-1 adherence is the key to successful SOX treatment. This study focused on…”
Get full text

Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy by Takahashi, Ryo, Ohashi, Manabu, Kano, Yosuke, Ida, Satoshi, Kumagai, Koshi, Nunobe, Souya, Chin, Keisho, Yamaguchi, Kensei, Nagino, Masato, Sano, Takeshi, Hiki, Naoki

“…Background Adjuvant S-1 monotherapy prolongs the survival of patients with pathological stage II or III gastric cancer undergoing D2 gastrectomy. This…”
Get full text

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer by Kato, Ken, Chin, Keisho, Yoshikawa, Takaki, Yamaguchi, Kensei, Tsuji, Yasushi, Esaki, Taito, Sakai, Kenji, Kimura, Masami, Hamaguchi, Tetsuya, Shimada, Yasuhiro, Matsumura, Yasuhiro, Ikeda, Ryuji

“…Summary Purpose NK105 is a new drug delivery system formulation for paclitaxel (PTX) whose recommended dose (RD)　is 150 mg PTX equivalent/m 2 administered…”
Get full text

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer by Yokota, Tomoya, Kato, Ken, Hamamoto, Yasuo, Tsubosa, Yasuhiro, Ogawa, Hirofumi, Ito, Yoshinori, Hara, Hiroki, Ura, Takashi, Kojima, Takashi, Chin, Keisho, Hironaka, Shuichi, Kii, Takayuki, Kojima, Yasushi, Akutsu, Yasunori, Matsushita, Hisayuki, Kawakami, Kentaro, Mori, Keita, Makiuchi, Takashi, Nagumo, Rie, Kitagawa, Yuko

“…Background A multicenter phase 2 trial analysed chemoselection with docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy (ICT) and…”
Get full text

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research by Takahari, Daisuke, Shinozaki, Eiji, Wakatsuki, Takeru, Ooki, Akira, Ozaka, Masato, Suzuki, Takeshi, Nakayama, Izuma, Osumi, Hiroki, Kamiimabeppu, Daisaku, Sato, Taro, Ogura, Mariko, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of…”
Get full text

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma by Bando, Hideaki, Kotani, Daisuke, Tsushima, Takahiro, Hara, Hiroki, Kadowaki, Shigenori, Kato, Ken, Chin, Keisho, Yamaguchi, Kensei, Kageyama, Shun-Ichiro, Hojo, Hidehiro, Nakamura, Masaki, Tachibana, Hidenobu, Wakabayashi, Masashi, Fukutani, Miki, Togashi, Yosuke, Fuse, Nozomu, Nishikawa, Hiroyoshi, Kojima, Takashi

“…The standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy (CRT) using…”
Get full text

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer by Yagi, Shusuke, Wakatsuki, Takeru, Yamamoto, Noriko, Chin, Keisho, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Fujisaki, Junko, Ishikawa, Yuichi, Yamaguchi, Kensei, Namikawa, Ken, Horiuchi, Yusuke

“…Background We recently reported the clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using surgical specimens; patients with…”
Get full text

Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy by Shitara, Kohei, Chin, Keisho, Yoshikawa, Takaki, Katai, Hitoshi, Terashima, Masanori, Ito, Seiji, Hirao, Motohiro, Yoshida, Kazuhiro, Oki, Eiji, Sasako, Mitsuru, Emi, Yasunori, Tsujinaka, Toshimasa

“…Background The Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) demonstrated a survival benefit by adjuvant S-1 monotherapy in patients who had…”
Get full text

Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma by Suzuki, Takeshi, Okamura, Akihiko, Watanabe, Masayuki, Mine, Shinji, Imamura, Yu, Asari, Takao, Osumi, Hiroki, Nakayama, Izuma, Ichimura, Takashi, Ogura, Mariko, Ooki, Akira, Takahari, Daisuke, Yamaguchi, Kensei, Chin, Keisho

“…Background The optimal treatment strategy for patients with borderline resectable (BR) esophageal squamous cell carcinoma (ESCC), in which tumors grow very…”
Get full text

Late Toxicity After Definitive Concurrent Chemoradiotherapy for Thoracic Esophageal Carcinoma by Morota, Madoka, M.D, Gomi, Kotaro, M.D, Kozuka, Takuyo, M.D., Ph.D, Chin, Keisho, M.D., Ph.D, Matsuura, Masaaki, Ph.D, Oguchi, Masahiko, M.D., Ph.D, Ito, Hisao, M.D., Ph.D, Yamashita, Takashi, M.D., PH.D

“…Purpose To evaluate late cardiopulmonary toxicities after concurrent chemoradiotherapy (CCRT) for esophageal carcinomas. Methods and Materials From February…”
Get full text

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer by Shimozaki, Keitaro, Shinozaki, Eiji, Yamamoto, Noriko, Imamura, Yu, Osumi, Hiroki, Nakayama, Izuma, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Ogura, Mariko, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei

“…Purpose Although RAS and PIK3CA mutations have been associated with resistance to anti-EGFR antibody in colorectal cancer or trastuzumab in breast cancer,…”
Get full text